Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Share-based Compensation (2016 - 2025)

ImmunityBio (IBRX) has disclosed Share-based Compensation for 12 consecutive years, with $8.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation fell 3.23% to $8.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $36.8 million, a 6.9% increase, with the full-year FY2025 number at $36.8 million, up 6.9% from a year prior.
  • Share-based Compensation was $8.7 million for Q4 2025 at ImmunityBio, down from $8.9 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $17.9 million in Q2 2021 to a low of $7.5 million in Q3 2024.
  • A 5-year average of $10.9 million and a median of $10.1 million in 2022 define the central range for Share-based Compensation.
  • Peak YoY movement for Share-based Compensation: skyrocketed 5447.52% in 2021, then tumbled 48.17% in 2024.
  • ImmunityBio's Share-based Compensation stood at $10.2 million in 2021, then dropped by 8.15% to $9.4 million in 2022, then surged by 36.62% to $12.8 million in 2023, then decreased by 29.25% to $9.0 million in 2024, then dropped by 3.23% to $8.7 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Share-based Compensation are $8.7 million (Q4 2025), $8.9 million (Q3 2025), and $9.6 million (Q2 2025).